Nykode Therapeutics AS (FRA:5VB) Dividends per Share: €0.09 (TTM As of Mar. 2026)


FRA:5VB Nykode Therapeutics AS FRA:5VB
37 GF Score
Price €0.25
GF Value €0.49
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Nykode Therapeutics AS Dividends per Share?

Nykode Therapeutics AS FRA:5VB -0.61% 37 Dividends per Share is €0.09 as of Mar. 2026. GuruFocus rates FRA:5VB with a GF Score™ of 37/100 and a GF Value™ of €0.49 (Possible Value Trap). The stock has 2 warning signs investors should review.

Nykode Therapeutics AS's dividends per share for the three months ended in Mar. 2026 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.09. Its Dividend Payout Ratio for the three months ended in Mar. 2026 was 0.00. As of today, Nykode Therapeutics AS's Dividend Yield % is 35.29%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Nykode Therapeutics AS  (FRA:5VB) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Nykode Therapeutics AS's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2026 )/ EPS without NRI (Q: Mar. 2026 )
=0/ -0.009
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

During the past 9 years, the highest Dividend Yield of Nykode Therapeutics AS was 67.03%. The lowest was 26.03%. And the median was 39.46%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Dividends per Share Related Terms

Nykode Therapeutics AS Dividends per Share Historical Data

* Premium members only.

The historical data trend for Nykode Therapeutics AS's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Dividends per Share Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividends per Share
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.08

Nykode Therapeutics AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Dividends per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.09 0.00 0.00 0.00

FRA:5VB vs VRTX, REGN, ALNY: Dividends per Share Comparison

For the Biotechnology subindustry, Nykode Therapeutics AS's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nykode Therapeutics AS Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Nykode Therapeutics AS's Dividend Yield % falls into.


FRA:5VB
37GF Score
Nykode Therapeutics AS FRA:5VB
Dividends per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nykode Therapeutics AS Dividends per Share Calculation

Dividends paid to per common share.

Frequently Asked Questions Learn more about Dividends per Share →
What does a Dividends per Share of €0.09 mean?
Nykode Therapeutics AS (FRA:5VB) has a Dividends per Share of €0.09 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's Dividends per Share too high?
Nykode Therapeutics AS's current Dividends per Share is €0.09. Overall, Nykode Therapeutics AS has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Dividends per Share compare to VRTX and REGN?
Nykode Therapeutics AS's Dividends per Share of €0.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Dividends per Share is €0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (FRA:5VB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.49, compared to a current price of €0.25 — trading 50% below its estimated fair value. The current Dividends per Share is €0.09. Nykode Therapeutics AS's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Nykode Therapeutics AS (FRA:5VB), the current Dividends per Share is €0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (FRA:5VB) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of €0.25 is trading 50% below its estimated GF Value™ of €0.49. GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.

Key valuation signals for FRA:5VB:

  • Dividends per Share: €0.09
  • GF Value™: €0.49 vs. price of €0.25 (50% below fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the FRA:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
37GF Score

Get the complete analysis for FRA:5VB

Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.25
Price
€0.49
GF Value